Literature DB >> 20397047

Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?

William D Chey1, Reema R Mody, Esin Izat.   

Abstract

BACKGROUND: Few studies have explored the satisfaction with proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD). AIM: The aim of this study was to assess patient and physician satisfaction with currently prescribed PPIs for patients with GERD.
METHODS: Separate online surveys were completed by 1,002 physicians and 1,013 GERD patients. Physician surveys examined satisfaction, symptom relief, long-term therapy, side-effects, breakthrough symptoms, and use of supplemental medications with PPIs. Patient surveys evaluated PPI regimen, length of therapy, satisfaction with PPI, symptom relief, use of supplemental medications, and perceptions about long-term use and side-effects.
RESULTS: Most respondents were satisfied with PPI therapy, but 35.4% of GERD patients and 34.8% of physicians perceived patients as "somewhat satisfied" to "completely dissatisfied" with PPI therapy. Patients who were highly satisfied were more likely to indicate complete symptom relief (P < 0.001) relative to patients who were less satisfied. However, over 35% of patients on once-daily and 54% on twice-daily PPI indicated that therapy failed to completely relieve symptoms. Patients who were highly satisfied were more likely to recommend medication to patients with the same symptoms (P < 0.001) and less likely to report that the medication is too expensive (P < 0.001), worry about long-term use (P < 0.001), or add OTC medications for supplemental control (P < 0.004).
CONCLUSIONS: Approximately one-third of GERD patients reported persistent symptoms and were dissatisfied with PPI therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20397047     DOI: 10.1007/s10620-010-1209-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

1.  Proton pump inhibitors: better acid suppression when taken before a meal than without a meal.

Authors:  J G Hatlebakk; P O Katz; L Camacho-Lobato; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  2000-10       Impact factor: 8.171

Review 2.  Treatment of gastroesophageal reflux disease.

Authors:  Michael Pettit
Journal:  Pharm World Sci       Date:  2005-12

Review 3.  Managing gastroesophageal reflux disease in primary care: the patient perspective.

Authors:  Harley Liker; Pali Hungin; Ingela Wiklund
Journal:  J Am Board Fam Pract       Date:  2005 Sep-Oct

4.  The burden of selected digestive diseases in the United States.

Authors:  Robert S Sandler; James E Everhart; Mark Donowitz; Elizabeth Adams; Kelly Cronin; Clifford Goodman; Eric Gemmen; Shefali Shah; Aida Avdic; Robert Rubin
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

Review 5.  Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease.

Authors:  C Donnellan; N Sharma; C Preston; P Moayyedi
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 6.  Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease.

Authors:  N Vakil
Journal:  Aliment Pharmacol Ther       Date:  2004-05-15       Impact factor: 8.171

7.  Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms.

Authors:  J F Bretagne; C Honnorat; B Richard-Molard; A Caekaert; P Barthélemy
Journal:  Aliment Pharmacol Ther       Date:  2006-03-01       Impact factor: 8.171

8.  Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort.

Authors:  P Wahlqvist; M Karlsson; D Johnson; J Carlsson; S C Bolge; M-A Wallander
Journal:  Aliment Pharmacol Ther       Date:  2008-02-29       Impact factor: 8.171

9.  Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome.

Authors:  J H Rubenstein; B Nojkov; S Korsnes; S A Adlis; M J Shaw; B Weinman; J M Inadomi; R Saad; W D Chey
Journal:  Aliment Pharmacol Ther       Date:  2007-08-01       Impact factor: 8.171

Review 10.  Long-term management of GERD in the elderly with pantoprazole.

Authors:  Carlo Calabrese; Anna Fabbri; Giulio Di Febo
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more
  15 in total

1.  The value of branded proton pump inhibitors: formulary considerations.

Authors:  David A Peura; Rosemary R Berardi; Javier Gonzalez; Louis Brunetti
Journal:  P T       Date:  2011-07

Review 2.  Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

Authors:  Xiaoxiao Yang; Yueyue Li; Yiyuan Sun; Mingming Zhang; Chuanguo Guo; Iqtida Ahmed Mirza; Yan-Qing Li
Journal:  Dig Dis Sci       Date:  2017-12-27       Impact factor: 3.199

Review 3.  Patient Values and Preferences Surrounding Proton Pump Inhibitor Use: A Scoping Review.

Authors:  Wade Thompson; Cody Black; Vivian Welch; Barbara Farrell; Lise M Bjerre; Peter Tugwell
Journal:  Patient       Date:  2018-02       Impact factor: 3.883

4.  Does Nissen Fundoplication Provide Lifelong Reflux Control? Symptomatic Outcome After 31-33 Years.

Authors:  P Neuvonen; J Sand; M Matikainen; T Rantanen
Journal:  World J Surg       Date:  2017-08       Impact factor: 3.352

5.  Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.

Authors:  Craig S Brown; Brittany Lapin; Chi Wang; Jay L Goldstein; John G Linn; Woody Denham; Stephen P Haggerty; Mark S Talamonti; John A Howington; Joann Carbray; Michael B Ujiki
Journal:  Surg Endosc       Date:  2015-02-13       Impact factor: 4.584

Review 6.  Dexlansoprazole - a new-generation proton pump inhibitor.

Authors:  Barbara Skrzydło-Radomańska; Piotr Radwan
Journal:  Prz Gastroenterol       Date:  2015-12-16

7.  Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?

Authors:  Richard H Hunt; Carmelo Scarpignato
Journal:  Clin Transl Gastroenterol       Date:  2015-10-29       Impact factor: 4.488

Review 8.  25 Years of Proton Pump Inhibitors: A Comprehensive Review.

Authors:  Daniel S Strand; Daejin Kim; David A Peura
Journal:  Gut Liver       Date:  2017-01-15       Impact factor: 4.519

Review 9.  Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR.

Authors:  Jeanetta W Frye; David A Peura
Journal:  Ther Clin Risk Manag       Date:  2015-10-30       Impact factor: 2.423

10.  Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers.

Authors:  Deok Y Yoon; Jung Sunwoo; Naree Shin; Ah R Kim; Bongtae Kim; Geun S Song; In-Jin Jang; SeungHwan Lee
Journal:  Clin Transl Sci       Date:  2021-01-21       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.